cyrilzakka/clinical-trials huggingface dataset:
Implementation of Gold Standard EMS CPR Programs for 2% Improvement in Survival Rates of Out-of-Hospital Cardiac Arrest in a Metropolitan City

This study aims to improve the survival rate of out-of-hospital cardiac arrest patients by 2% through a bundle of three intervention measures including: 1) dispatcher-assisted CPR, 2) multi-tiered response team CPR, and 3) feedback CPR.

The project aims to implement gold standard emergency medical services (EMS) cardiopulmonary resuscitation (CPR) programs, which will result in increased bystander CPR, reduced EMS response time, and high quality CPR during prehospital resuscitation through a bundled approach including 1) dispatcher-assisted CPR (DA-CPR), 2) multi-tiered response team CPR, and 3) feedback CPR.

The DA-CPR program aims to contribute to improved bystander CPR rate and reduced EMS response time interval through rigorous monitoring of cardiac arrest detection at primary call receiving stage as well as increased number of dispatcher-assisted CPR instruction initiation in the target time of 90 seconds. The Team CPR protocol will render synergetic efforts among participating EMS personnel from both basic life support (BLS) and advanced life support (ALS) units within the new tiered dispatch system and subsequently deliver uninterrupted CPR to out-of-hospital cardiac arrest (OHCA) patients before hospital arrival. The feedback CPR monitoring and quality assurance program will contribute to high quality CPR delivered to the patients on the scene as well as during transport.

Eligibility Criteria:
Inclusion Criteria:

* EMS-assessed OHCA
* Cardiac etiology
* Above 15 years of age

Exclusion Criteria:

* Patients who do not receive EMS resuscitation
* Patients with signs of evident death (decapitation, evident livor mortis or rigor mortis)
* Do-Not-Resuscitate cases
* Pregnant patients
* Patients whom the mechanical devices cannot be applied to
Effects of Treating Obstructive Sleep Apnea in Epilepsy

The purpose of this trial is to work out design issues prior to conducting a definitive phase 3 trial to determine whether treating sleep-related breathing disorders in people with epilepsy results in improvement in seizure control or an improvement in alertness during the day.

Despite appropriate treatment with medications, individuals with epilepsy often continue to have seizures, and many suffer from excessive daytime sleepiness and poor quality of life. Evidence from case studies suggests that treatment of coexisting obstructive sleep apnea (OSA)-stoppage in breathing during sleep-can reduce the frequency of seizures in people with epilepsy that is resistant to antiepileptic medication.

In this study, individuals with symptoms of OSA and 2 or more seizures a month who meet study criteria will undergo polysomnography, a test that continuously monitors normal and abnormal physiological activity during sleep. Those individuals who test positive for OSA will be randomized to either therapeutic or placebo continuous positive airway pressure (CPAP)-a mask treatment for sleep apnea-for 10 weeks, during which time seizure frequency, daytime sleepiness, health-related quality of life, and CPAP compliance will be assessed.

Eligibility Criteria:
Inclusion Criteria:

* Age of 18 years or older.
* A history supportive of obstructive sleep apnea.
* Subject is able and willing to provide informed consent and to cooperate with polysomnography.
* Four or more quantifiable seizures per month.
* Subjects and their physicians agree to have their medication regimens optimized so that they are on the best regimen titrated to therapeutic benefit prior to the baseline phase of the study.

Exclusion Criteria:

* Seizures secondary to drugs, alcohol, infection, neoplasia, demyelination, metabolic illness, or progressive degenerative disease.
* Non-epileptic spells (e.g., pseudoseizures) alone or in combination with epileptic seizures.
* Narcolepsy or another primary sleep disorder that requires intervention with medications and which may affect results of study (e.g., severe periodic limb movement disorder).
* Effectively treated OSA or prior exposure to continuous positive airway pressure.
* History of poor compliance with antiepileptic medications.
* Current treatment with the vagus nerve stimulator.
* Pregnancy.
* A significant history of medical or psychiatric disease which may impair participation in the trial.
* A history of alcohol or drug abuse during the one-year period prior to trial participation.
* Evidence of medical instability (e.g., congestive heart failure, cardiac arrhythmias, pulmonary disease) due to obstructive sleep apnea.
* Subjects who are unaware of the majority of their seizures and lack a reliable witness.
* Greater than ten seizures a day.
A Study Reviewing Medical Records of Adults With Helicobacter Pylori Infections in China

The main aim of the study is to review treatment therapies in people with Helicobacter pylori (H. pylori) infections in standard hospital settings in China.

In this study, the study doctors will review medical records of participants who have had H. pylori infections any time from 1st January 2019 to 31st December 2021. This study is about collecting existing data only; participants are not treated and do not need to visit a study doctor during this study.

This is a non-interventional, retrospective cohort study of participants who have evidence of H. pylori infection using pre-existing electronic medical record data in China. This study will evaluate the distribution of methods of eradication therapy among participants who received medications that were used in the eradication therapy for H. pylori infection.

Retrospective de-identified participant-level data will be collected primarily from hospitals in China between 1st January 2019 to 31st December 2021. The extracted electronic medical record dataset will include patient demographic information, visit information, diagnosis information, treatment information, and cost information (if available). All the participants will be assigned to a single observational cohort:

• Participants with H. pylori

This multi-center study will be conducted in China. The overall study duration will be approximately 54 months.

Eligibility Criteria:
Inclusion Criteria:

1. Participants with a record of H. pylori infection diagnosis or positive result of H. pylori diagnostic testing between 1st January 2019 and 31st December 2021.

Exclusion Criteria:

Not applicable.
Effect of Inverse Ratio Ventilation During Induction of General Anesthesia on Safe Apnea Time in Obese Patients

The purpose of this study is to investigate the clinical application value of inverse ratio ventilation in obese patients during induction of general anesthesia by studying the effect of inverse ratio ventilation on the safe apnea time.

Inverse ratio ventilation(IRV) can produce mean airway pressure(Pmean)similar to external positive end expiratory pressure(Peep) by increasing inspiratory time. Moreover, the increase of Pmean was not accompanied by the further increase of peak airway pressure (Ppeak) and airway plateau pressure (Pplat), while the application of external peep accompanied with the increase of Pplat increased the risk of barotrauma . High level of Peep increased cardiac load and decreased cardiac output. A number of studies have found that the hemodynamic stability of patients can be achieved when IRV regulates the inspiratory / expiratory ratio in an appropriate range (I: E \< 2:1). Therefore, the inverse ratio is considered to be superior to Peep in terms of gas exchange and respiratory mechanics.

Eligibility Criteria:
Inclusion Criteria:

* Obese patients, aged 18-65 years, of either gender, ASA grade II-III, body mass index (BMI) \> 30 kg / m2, scheduled for general anesthesia under tracheal intubation, signed informed consent.

Exclusion Criteria:

* Patients who need rapid sequence induction (RSI); patients with expected difficult airway; severe chronic respiratory diseases, such as tuberculosis, bronchitis, bronchial asthma and COPD; patients with severe cardiovascular diseases, such as severe ischemic heart disease and pulmonary hypertension; patients with severe cerebrovascular diseases, such as cerebral hemorrhage and cerebral infarction; patients with abnormal basal metabolic rate, such as pregnancy, thyrotoxicosis, pheochromocytoma; and severe stomach reflux disease; patients with abnormal hemoglobin and hematocrit.
Vaginal Innate Immunity in Normal and HIV-Infected Women

The innate immunity of the vaginal tract provides first-line defense from abnormal microorganisms or overgrowth of common organisms, such as Candida species or Gardnerella vaginalis. It is unclear from the current available literature whether the rate of vaginal infection increases or decreases in frequency during pregnancy when compared to the non-pregnant state, but this may be predicted by shifts in vaginal innate immunity. Vaginal infections are important players in HIV disease, potentially increasing the risk of viral transmission. In addition, these infections may activate inflammatory markers in the reproductive tract and increase the risk of premature delivery or other negative pregnancy outcomes. The vaginal innate immune system has not been well characterized in pregnant women, or in women with HIV infection. The study of how this system changes in pregnancy and HIV infection will provide essential knowledge for further study of vaginal mucosal protection.

The investigators study is an observational study designed to compare levels of vaginal innate immunity markers in women based on a) pregnancy status and b) HIV infection status. Comparisons will be made between pregnant and non- pregnant women and between HIV positive and HIV negative women. The investigators hypothesize that there will be significant differences in levels of innate immunity between the groups.


Eligibility Criteria:
Inclusion Criteria:

* Female
* Age 18 - 40 years
* Able to provide informed consent

Exclusion Criteria:

* Women with the following conditions will be excluded:
* Currently active Syphilis or Herpes simplex infection
* Other (non-HIV) comorbid conditions causing acute or chronic inflammatory states or immunosuppression (i.e., transplant recipients, active systemic lupus)
* Current use of hormonal birth control or with IUD in place
* History of Hysterectomy or bilateral oophorectomy

Women with the following conditions will require rescheduling of the study visit:

* Use of hot tub or pool, vaginal creams, douches, vaginal medications, or vaginal intercourse within 48 hours
* Current vaginal bleeding
* Recent treatment for vaginal infection will require 4 - 6 week delay in enrollment

Pregnant women with the following conditions at the time of examination will be excluded:

* Active labor or other conditions of duress
* Signs or symptoms of preterm labor
* Vaginal bleeding
* Placenta previa
* History of prior preterm birth
* Ruptured amniotic membranes
* Multifetal gestation
* Stillbirth or intrauterine fetal demise (IUFD)
A Smartphone App for Women With Primary Dysmenorrhea

With a randomized, pragmatic study the effectiveness of a smartphone app for menstrual pain in 18-34-year-old women with primary dysmenorrhea will be investigated.

Smartphone apps may be useful to guide and support individuals in self-management strategies. Primary dysmenorrhea is a very common problem for women. With a randomized, pragmatic study the investigators aim to evaluate whether a smartphone app for women with menstrual pain is effective in reducing menstrual pain in 18-34-year-old women with primary dysmenorrhea. For this the investigators compare the complete smartphone app with two control versions of this app. The complete app provides evidence-based self-care information and instructions for self-acupressure in menstrual pain, the control intervention I includes self-care information, but no instructions for self-acupressure, and control intervention II includes instructions for self-acupressure, but no self-care information. The investigators aim to observe 594 women with primary dysmenorrhea over 12 menstruation cycles. The primary outcome is the mean pain intensity on the days with pain during the 6th menstruation after randomization using a numerical rating scale (NRS; 0=no pain; 10=strongest pain imaginable). Women are eligible when they suffer from primary dysmenorrhea, are between 18 and 34 years old, not pregnant and do not plan to be pregnant within the next 12 months.

Eligibility Criteria:
Inclusion Criteria:

* Female, aged 18-34 years
* Dysmenorrhea, defined as self-reported menstrual cramps or pain during every menstrual cycle which started during the teenage years
* No prior history of a gynecological disease that is known to be a reason for the dysmenorrhea
* Not more than 5 days with menstrual pain outside the menstrual period itself
* Menstruation within the last six weeks and a cycle length of 3 to 6 weeks
* Moderate or severe pain, defined as a score equal to or higher than 6 on a numeric rating scale (NRS, 0 to 10) for the worst pain intensity during the last menstruation
* Informed consent
* Possession of an iPhone
* Willingness and ability to input and share anonymous data through the study app
* The willingness to see a doctor when 1) pain is getting worse than usual, 2) pain medication is not helping, and 3) when the pain is still present well before or well after the period.

Exclusion Criteria:

* Known pregnancy
* Pregnancy already planned for the forthcoming 12 months
Changes of Oral and Intestinal Microbiota After Bariatric Surgery

Purpose

The aim of this study was to analyze the changes of microbiota among patients undergoing LSG or LRYGB on two levels of gastrointestinal tract (using oral swab and stool sample). We compared samples from patients before and after bariatric operation.

Materials and methods This prospective cohort study was conducted in one academic, teaching hospital. The recommendations of the Metabolic and Bariatric Surgery Section of the Polish Surgical Society were used as indication for surgery, that is: Body Mass Index (BMI) ≥35 kg/m2 with obesity-related comorbidities or BMI ≥40 kg/m2.

Analysis and endpoints

Primary endpoint was to determine the difference in microbiota present in oral cavity and large intestine between patients before and after bariatric surgery. Secondary endpoint was to compare the difference in microbiota changes between patients undergoing LSG and LRYGB


Eligibility Criteria:
Inclusion Criteria:

* informed consent to participate in the study
* meeting the eligibility criteria for bariatric treatment (either for LSG or LRYGB).

Exclusion Criteria:

* treatment with antibiotics within 30 days prior to gathering microbiological material
* gastrointestinal infections
* inflammatory bowel disease
* thyroid diseases
* cancer (especially the digestive tract)
* immunodeficiency.
Monopolar Scissors vs Bipolar Vessel Sealer vs Ultrasonic Shears: A Prospective Randomized Study in Laparoscopic Colorectal Surgery

Monopolar electro surgery scissors (MES), electro thermal bipolar vessel sealer (BVS) and ultrasonically coagulating shears (UCS) are all applied in laparoscopic colorectal surgery. We aimed to compare the different devices with regard to dissection time, blood loss, technical aspects and costs.

* Trial with surgical intervention


Eligibility Criteria:
Inclusion criteria: All patients undergoing laparoscopic left-sided colorectal resection.

Exclusion criteria: \< 18 years no informed consent restricted communication abilities (language, mental illness)
Biological Stardadization of D. Pteronyssinus and D. Farinae Allergen Extracts

Four concentrations of Dermatophagoides pteronyssinus and Dermatophagoides farinae allergen extracts, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm..

This is an open, unblinded and non-randomized biological assay. The study design is a slight modification of the recommendations proposed by the Nordic Guidelines.

Eligibility Criteria:
Inclusion Criteria:

* Clinical history positive inhalation allergy (rhinitis I rhinoconjunctivitis I asthma) against Dermatophagoides pteronyssinus or Dermatophagoides farinae.
* A prick-test positive (average of the papule ≥ 3 mm diameter) with a summary of the same allergen I presence against the allergen specific Immunoglobulin E.
* The average area of the papule obtained by histamine dihydrochloride to 10 mgml must be greater than or equal 7 mm2.
* Age: over 18 years of age.
* Both sexes.

Exclusion Criteria:

* Subjects outside of the age range.
* Individuals who have previously received immunotherapy in the last 5 years for the treatment of asthma or the allergic rhinoconjunctivitis induced by allergens that may interfere with the extract mixture of Dermatophagoides pteronyssinus or farinae.
* Subjects with important symptoms of rhinoconjunctivitis I bronchial asthma in which the suspension of the antihistamine treatment for systemic is contraindicated.
* Subjects that have previously submitted a serious secondary reaction during skin prick test diagnostic tests.
* Subjects in treatment with ss-blockers.
* Unstable subjects of clinical point of view (asthma acute, febrile, etc.).
* Subjects with lesions of active hives, severe active dermographism, severe atopic dermatitis, sunburn, eczema, lesions of psoriasis in the area of realization of the prick test (risk of false positives).
* Subjects with viral infection activates the herpes simplex or herpes varicella-zoster in the area of realization of the prick test.
* Subjects that have some pathology in which the administration of adrenaline (hyperthyroidism, hypertension, heart disease, etc.) is contraindicated.
* States of the subject that can not offer cooperation and severe psychiatric disorders.
* Pregnant or women at risk of pregnancy and breastfeeding women.
Nutritional Status in Retroperitoneal Sarcoma.

Prospective feasibility study of perioperative nutrition in patients affected by primary retroperitoneal sarcoma

Aim of our study was to investigate the feasibility of a prehabilitation policy to optimize protein energetic reserves in a group of patients affected by primary localized RPS, candidate to a multiple organ resection surgery, as well as the feasibility of a standardized nutritional postoperative caloric target and its adequacy.

Eligibility Criteria:
Inclusion Criteria:

- every patient with retroperitoneal sarcoma scheduled for surgery

Exclusion Criteria:

* chronic renal failure
* diabetes mellitus
* emergency surgery
* physical status classification system ASA\>3
* any contraindication to arterial catheter in Femoral artery for PICCO hemodynamic monitoring
Comparison of Diclofenac vs. Nepafenac Ophthalmic Drops: Patient Comfort

In this study we test Diclofenac and Nepafenac and compared patients experience and comfort following administration of these ophthalmic drops.

In this study we will compare the ocular tolerability between preservative-free Diclofenac and Nepafenac drops. Using a standard comparative scale we will measured discomfort, itching, burning and pain in intervals of 1 sec, 5 sec, 1 min and 5 min post-administration.

The results may aid both doctors and patients in decision regarding the post surgical anti-inflammatory treatment.

Eligibility Criteria:
Inclusion Criteria:

* patient facing cataract surgery

Exclusion Criteria:

* under 18
* cognitive decline
A Comparison of Endoscopic Surgery and Exercise Therapy in Patients With Longstanding Achilles Tendinopathy

Exercise is a preferred treatment modality for mid-portion achilles tendinopathy. Despite this, as many as 44 % of achilles tendinopathy patients do not respond to exercise treatment.

Surgery for midportion achilles tendinopathy has for many years been done as an open procedure. New knowledge resulted in a variety of minimally invasive procedures and the development of endoscopic surgery.

In this study, the effect of non-open surgery and conservative treatment (physiotherapy and exercises) will be compared.


Eligibility Criteria:
Inclusion Criteria:

* diagnosis of mid-portion achilles tendinopathy
* pain during at least 3 months
* decreased function (a score less than 80 on VISA-A)

Exclusion Criteria:

* Physiotherapy during previous three months
* history of major achilles trauma
* cardiovascular, respiratory, systemic, or metabolic conditions limiting exercise tolerance
Training About Sudden Infant Death Syndrome

Sudden infant death syndrome, which constitutes a significant proportion of all infant deaths, is associated with various preventable risk factors. The study aims examine effects of training provided to pregnant women about risk factors triggering sudden infant death syndrome before birth on the post-partum knowledge level and behaviors of mothers.

Sudden infant death syndrome, which constitutes a significant proportion of all infant deaths, is associated with various preventable risk factors. To examine effects of training provided to pregnant women about risk factors triggering sudden infant death syndrome before birth on the post-partum knowledge level and behaviors of mothers. Pre-test post-test designed, randomized controlled, experimental study was conducted in Turkey, 2024. Sixty pregnant women were employed in intervention and control groups. Face-to-face training on risk factors triggering sudden infant death syndrome was provided to pregnant women in intervention group. Study data were collected using "Personal Information Form, Knowledge Level on Sudden Infant Death Syndrome and Risky Behavior Identification Questionnaire". Data were collected face to face before training and after training and via telephone 2 months after training.

Eligibility Criteria:
Inclusion Criteria:

* Pregnant women who were in the 38th week of their pregnancy and older,
* Lived a healthy pregnancy,
* Had no communication problems,
* Can speak and understand Turkish,
* Agreed to participate in the study were included.

Exclusion Criteria:

* Pregnant women who were earlier than 38 weeks pregnant,
* Had difficulty in communicating,
* Were illiterate and unable to speak Turkish,
* Who filled out the forms incompletely were not included.
Investigation of Filaggrin Gene Mutations Among Latinx Patients With Atopic Dermatitis

The study, Investigation of Filaggrin Gene Mutations among Latinx patients with Atopic Dermatitis, will examine the association between pathogenic FLG LOF variants and AD in a new population of Latinx patients for which clinical and disease characteristics will be well-described.

Filaggrin deficiency is considered a major target for therapy in Atopic Dermatitis (AD).43 The current status quo with regards to FLG LOF mutations as the strongest known genetic risk factor in AD stems from incomplete data as the majority of studies that have previously examined this association have been carried out in only a limited group of populations (i.e., European ancestry).30 Such partial data impedes our full understanding of genetic risk in AD and consequently has implications for disease prognosis and management. The proposed research represents an attempt to examine long-held paradigms in AD as they relate to genetic risk factors and disease. The development of an independent cohort of Latinx subjects with physician-confirmed diagnosis of AD that is also well phenotyped and grouped by ancestry, while also capturing measures of disease severity, will provide the opportunity to examine a population that has been largely absent from prior studies and further advance our understanding of the pathogenomic role FLG LOF variants in AD.

Eligibility Criteria:
Inclusion Criteria:

* Established diagnosis of AD based on physician report of at least one-year duration
* Self-identification as Latino/Latinx or Hispanic

Exclusion Criteria:

-